IAG, Image Analysis Group & Collaborators Present the Latest Data at ACR 2020

IAG, Image Analysis Group & Collaborators Present Latest Data at ACR 2020

A number of abstracts by IAG’s team and scientific and industry collaborators were accepted for presentation at the American College of Rheumatology Annual Meeting, 2020.  This global meeting brings together researchers, clinicians and industry and facilitates boundless opportunities for professional development, networking, and first-hand access to the latest rheumatology research and clinical applications.

IAG’s accepted abstracts present the data from the latest clinical research trials and Investigator Initiated Studies and involve state-of-the-art and cutting-edge advanced imaging techniques, our quantitative methodologies for assessment of treatment efficacy, including some that are based on Machine Learning and AI principals.

The accepted abstracts are:

Role of Artificial Intelligence in Assessment of Peripheral Joint MRI in Inflammatory Arthritis: A Systematic Review and Meta-analysis.  Arya Haj-Mirzaian, Olga Kubassova, Mikael Boesen, Paul Bird, John A. Carrino

SESSION INFORMATION

Date: Monday, November 9, 2020

Session Title: Imaging of Rheumatic Diseases Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

This paper discussed AI-based methods for MRI, Contrast Enhanced MRI and Dynamic Contrast Enhanced MRI, used in 28 Rheumatoid Arthritis clinical studies, where 1342 MRIs were analyzed. Our meta-regression analysis showed that computer-aided and manual methods provide comparable reliability for quantification of bone erosion, synovitis, and perfusion parameters (P>0.05) and that AI-based methods demonstrate feasibility, reliability and validity when utilized to quantify MRI pathologies of peripheral joints in patients with inflammatory

Evaluation of a Patient-reported Frailty Tool in Women with Systemic Lupus Erythematosus.

Sarah Lieber, Stephen Paget, Jessica Berman, Medha Barbhaiya, Lisa Sammaritano, Kyriakos Kirou, John Carrino, Musarrat Nahid, Mangala Rajan, Dina Sheira and Lisa Mandl

SESSION INFORMATION

Date: Sunday, November 8, 2020

Session Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

This abstract presents a patient-reported frailty tool and evaluates it alongside a standard frailty measure in SLE. With the data from 72 female patients, the abstract discusses 1) the prevalence of frailty according to both the standard Fried phenotype (FP) and a validated self-reported frailty instrument, 2) differences between frail and non-frail women according to each definition, 3) the association of each frailty measure with patient-reported disability, and 4) the correlation between frailty definitions.

Digital Artery Volume Index (Davix©) Predicts Onset of Future Digital Ulcers in Patients with Systemic Sclerosis, Klodian Gjeloshi, Giovanni Lettieri, Fiammetta Danzo, Giuseppina Abignano, Mark Hinton, Anne-Maree Dean, Giovanna Cuomo, Olga Kubassova and Francesco Del Galdo

SESSION INFORMATION

Date: Sunday, November 8, 2020

Session Title: Systemic Sclerosis & Related Disorders – Clinical Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

This abstract work is a continuation of our work on development and validation of digital artery volume index (DAVID). This study demonstrates that DAVIX© is a feasible surrogate outcome measure of neointima proliferation in SSc and a useful predictive imaging biomarker of vascular disease activity.

Doppler Ultrasound Predicts Successful Discontinuation of Biological DMARDs in Rheumatoid Arthritis Patients in Sustained Clinical Remission. Lene Terslev, Cecilie Hegaard Brahe, Merete Hetland, Stylianos Georgiadis, Karen Ellegaard, Lars Juul, Uffe Døhn, Viktoria Fana, Torsten Møller, Simon Krabbe, Lykke Ørnbjerg, Daniel Glinatsi, Tuan Khai Huynh, Natalia Manilo, Dorte Vendelbo Jensen, Karsten Asmussen, Mikael Boesen, Zoreh Rastiemadabadi, Lone Morsel-Carlsen, Jakob Møller, Henrik Røgind, Annette Hansen, Jesper Nørregaard, Søren Jacobsen, Niels Steen Krogh and Mikkel Østergaard,

SESSION INFORMATION

Date: Monday, November 9, 2020

Session Title: Imaging of Rheumatic Diseases Poster

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

There is an increasing interest in tapering or even discontinuing biological disease-modifying anti-rheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients in sustained remission. This abstract, co-authored by two members of IAG’s Scientific Advisory Board aims to assess the potential role of ultrasound for predicting successful tapering and successful discontinuation.

Weight Loss as Treatment for Gout in Patients with Concomitant Obesity: A Proof-of-Concept Randomized Controlled Trial. Kristian Zobbe, Robin Christensen, Sabrina Mai Nielsen, Lisa Stamp, Marius Henriksen, Anders Føhrby Overgaard, Lene Dreyer, Filip Krag Knop, Jasvinder Singh, Michael Doherty, Pascal Richette, Arne Astrup, Karen Ellegaard, Else Marie Bartels, Mikael Boesen, Henrik Rindel Gudbergsen, Henning Bliddal and Lars Erik Kristensen.

SESSION INFORMATION

Date: Saturday, November 7, 2020

Session Title: Metabolic & Crystal Arthropathies Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

This is a study of an intensive dietary intervention showing that it can effectively lower body weight in people with gout and concomitant obesity.

We look forward to this exciting meeting, in a new virtual format! Warmest thanks to our collaborators, scientific advisors and biotechnology and pharmaceutical partners for their contributions.

If you are planning a clinical trial to treat #lupus, inflammatory #arthritis, #gout, #osteoarthritis and other musculoskeletal and rheumatic diseases, speak to our expert team!

Email: imaging.experts@ia-grp.com

About IAG, Image Analysis Group

Our goal is to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. We take a broader view on the assets’ development and bring expertise in study design, execution, and commercialization. As needed, we deploy AI, Machine Learning, and smart image analysis methods to ensure the speed and cost-effectiveness of clinical programs. IAG’s team supports investors and biotech executive teams with deploying the right strategies for early efficacy assessments, objective response prediction and critical analysis of advanced treatment manifestations. Thus, lowering the investment risks into advanced therapies while helping to accelerate study outcomes. www.ia-grp.com

Engage with our team

Dr. Olga Kubassova, CEO: www.linkedin.com/in/olgakubassova/

Dr. Mikael Boesen, Lead for Musculoskeletal and Rheumatic Clinical Research, www.linkedin.com/in/mikael-boesen-81a5b72/

News
Events